Adicet bio provides corporate update and highlights expected 2025 milestones

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025. “2024 was a momentous year for adicet as we amplified our efforts in autoimmune diseases and solid tumors. we dosed our first patients in our clinical trials evaluating our gamma delta 1 chimeric a.
ACET Ratings Summary
ACET Quant Ranking